Acute Toxicity of CKD-602, a New Anticancer Agent, in Rats |
Kim, Jong-Choon
(College of Veterinary Medicine, Chonnam National University)
Shin, Dong-Ho (College of Veterinary Medicine, Chonnam National University) Kim, Sung-Ho (College of Veterinary Medicine, Chonnam National University) Kim, Joon-Kyun (Medicinal Research Center, Chong Kum Dang Co.) Cha, Shin-Woo (Korea Institute of Toxicology) Han, Jung-Hee (Korea Institute of Toxicology) Suh, Jeong-Eun (Korea Institute of Toxicology) Chung, Moon-Koo (Korea Institute of Toxicology) |
1 | Lee, J. H., Lee, J. M., Kim, J. K., Ahn, S. K., Lee, S. J., Kim, M. Y., Jew, S. S., Park, J. G. and Hong, C. I. (1998). Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)- camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res., 21, 581-590 DOI ScienceOn |
2 | Bleiberg, H. and Rothenberg, M. L. (1996). CPT-11: From DNA topology to clinical activity. Semi. Oncol., 23, I-50 |
3 | Chatelut, E., Delord, J. P. and Canal, P. (2003). Toxicity patterns of cytotoxic drugs. Invest. New Drugs, 21, 141-148 DOI ScienceOn |
4 | Dahut, W., Harolod, N., Takimototo, C., Allegra, C., Chen, A., Hamilton, J. M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, W. and Grem, J. (1996): Phase I and pharmacokinetic study of 9-aminocamptothecin given as a 72-hour infusion in adult cancer patients. J. Clin. Oncol., 14, 1236-1244 DOI |
5 | Hashimoto, H., Chatterjee, S. and Berger, N.A. (1995). Mutagenic activity of topoisomerase I inhibitors. Clin. Cancer Res., 1, 369-376 |
6 | Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R, Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K. and Kingsbury, W. D. (1989). Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32,715-720 DOI |
7 | Kim, J. H., Lee, S. K., Lim, J. L., Shin, H. J. and Hong, C. I. (2002): Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics. Int. J. Pharm., 239, 207-211 DOI ScienceOn |
8 | Kim, E. J., Lee, R. K., Suh, J. E., Han, S. S. and Kim, J. K. (2003a). Safety pharmacology of CKD-602, a novel anticancer agent. Arzneimittel forschung, 53, 272-279 |
9 | Kim, J. C.; Kim, K. H. and Chung, M. K. (1999): Testicular cytotoxicity of DA -125, a new anthracycline anticancer agent, in rats. Reprod. Toxicol., 13, 391-397 DOI ScienceOn |
10 | Kim, J. C., Kim, S. H., Shin, D. H., Ahn, T. H., Kim, H. C., Kim, Y. B., Jiang, C. Z., Han, J. and Chung, M. K. (2004). Effects of prenatal exposure to the environmental pollutant 2-bromopropane on embryo-fetal development in rats. Toxicology, 196, 77-86 DOI ScienceOn |
11 | Kim, J. C., Shin, D. H., Ahn, T. H., Kang, S. S., Song, S. W., Han, J., Kim, C. Y., Ha, C. S. and Chung, M. K. (2003b). 26-Week repeated oral dose toxicity study of the new quinolone antibacterial DW-116 in Sprague-Dawley rats. Food Chem. Toxicol., 41, 637-645 DOI ScienceOn |
12 | Kolimannsberger, C., Mross, K., Jakob, A., Kanz, L. and Bokemyer, C. (1999). Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56, 1-12 DOI ScienceOn |
13 | Lee, J. H., Lee, J. M., Lim, K. H., Kim, J. K., Ahn, S. K., Bang, Y. J. and Hong, C. I. (2000). Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivativ. Ann. N. Y. Acad. Sci., 922, 324-325 |
14 | Moertel, C. G., Schutt, A. J., Reitmeier, R. J. and Hahn, R. G. (1972). Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101 |
15 | Slichenmyer, W. J. and Rowinsky, E. K. (1993). The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85, 271-291 DOI |
16 | Pizzolato, J. F. and Saltz, L. B. (2003). The camptothecins. Lancet, 361, 2235-2242 DOI ScienceOn |
17 | Pratesi, G., Tortoreto, M., Corti, C., Giardini, R. and Zunino, F. (1995). Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Brit. J. Cancer, 71, 525-528 DOI ScienceOn |
18 | SAS Institute, Inc, (1997). SAS/STAT Software: Changes and Enhancements Through Release 6.12. SAS Institute, Cary, NC |
19 | Takimoto, C. H., Wright, J. and Arbuck, S. G. (1998). Clinical applications of the camptothecins. Biochim. Biophys. Acta, 1400, 107-119 DOI ScienceOn |
20 | Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T. and Block, J. B. (1970). Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54, 461-470 |